TrialQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2019

Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.

David F McDermott et al.PubMed ↗Publisher ↗

No numbers read from the abstract.